{"id":"https://openalex.org/W7225045461","doi":"https://doi.org/10.5281/zenodo.23851353","title":"Neuroleptic Agent Toxicity: A Comprehensive Review of Mechanisms, Clinical Manifestations, and Management Strategies","display_name":"Neuroleptic Agent Toxicity: A Comprehensive Review of Mechanisms, Clinical Manifestations, and Management Strategies","publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225045461","doi":"https://doi.org/10.5281/zenodo.23851353"},"language":"en","primary_location":{"id":"doi:10.5281/zenodo.23851353","doi":"https://doi.org/10.5281/zenodo.23851353","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23851353","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"volume":null,"type":"article","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.5281/zenodo.23851353","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5136784467","display_name":"Indunil Karunarathna","orcid":"https://orcid.org/0009-0009-7189-3049","observed_orcids":["https://orcid.org/0009-0009-7189-3049"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Indunil Karunarathna","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-7189-3049","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5140069502","display_name":"Asoka Karunarathna","orcid":"https://orcid.org/0009-0009-7189-3049","observed_orcids":["https://orcid.org/0009-0009-7189-3049"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Asoka Karunarathna","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-7189-3049","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.88357364,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11635","display_name":"Poisoning and overdose treatments","score":0.5723000168800354,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11635","display_name":"Poisoning and overdose treatments","score":0.5723000168800354,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.2896000146865845,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.10949999839067459,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8840000033378601},{"id":"https://openalex.org/keywords/neuroleptic-malignant-syndrome","display_name":"neuroleptic malignant syndrome","score":0.8769999742507935},{"id":"https://openalex.org/keywords/dopamine-d2-receptor-antagonism","display_name":"dopamine D2 receptor antagonism","score":0.972000002861023},{"id":"https://openalex.org/keywords/dopaminergic-pathways","display_name":"dopaminergic pathways","score":0.6959999799728394},{"id":"https://openalex.org/keywords/serotonin-receptors","display_name":"serotonin receptors","score":0.3499999940395355},{"id":"https://openalex.org/keywords/histamine-receptors","display_name":"histamine receptors","score":0.7429999709129333},{"id":"https://openalex.org/keywords/cholinergic-receptors","display_name":"cholinergic receptors","score":0.8740000128746033},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7160000205039978},{"id":"https://openalex.org/keywords/emergency-department-visits","display_name":"emergency department visits","score":0.7689999938011169},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.7540000081062317},{"id":"https://openalex.org/keywords/drug-switching","display_name":"drug switching","score":0.8970000147819519},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.6919999718666077},{"id":"https://openalex.org/keywords/drug-monitoring","display_name":"drug monitoring","score":0.3190000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7026000022888184},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6413000226020813},{"id":"https://openalex.org/C2777964233","wikidata":"https://www.wikidata.org/wiki/Q1424956","display_name":"Neuroleptic malignant syndrome","level":2,"score":0.6087999939918518},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5605000257492065},{"id":"https://openalex.org/C3017459112","wikidata":"https://www.wikidata.org/wiki/Q162657","display_name":"Neurotransmitter systems","level":3,"score":0.4814999997615814},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.44440001249313354},{"id":"https://openalex.org/C2776286997","wikidata":"https://www.wikidata.org/wiki/Q2880966","display_name":"Dopaminergic pathways","level":4,"score":0.43320000171661377},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.430400013923645},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.37860000133514404},{"id":"https://openalex.org/C2778176773","wikidata":"https://www.wikidata.org/wiki/Q2976049","display_name":"Drug class","level":3,"score":0.3727000057697296},{"id":"https://openalex.org/C156927020","wikidata":"https://www.wikidata.org/wiki/Q1187783","display_name":"Neurotransmitter receptor","level":3,"score":0.366100013256073},{"id":"https://openalex.org/C137627325","wikidata":"https://www.wikidata.org/wiki/Q156318","display_name":"Etiology","level":2,"score":0.3596999943256378},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3391000032424927},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.3296000063419342},{"id":"https://openalex.org/C138816342","wikidata":"https://www.wikidata.org/wiki/Q189603","display_name":"Public health","level":2,"score":0.32589998841285706},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.31859999895095825},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.2946000099182129},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.29100000858306885},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.29010000824928284},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.28529998660087585},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.27880001068115234},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.2694000005722046},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.2644999921321869},{"id":"https://openalex.org/C2910715078","wikidata":"https://www.wikidata.org/wiki/Q162657","display_name":"Neurotransmitter Agents","level":4,"score":0.25949999690055847},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.2590000033378601},{"id":"https://openalex.org/C2778689640","wikidata":"https://www.wikidata.org/wiki/Q113259","display_name":"Anticholinergic","level":2,"score":0.2581999897956848}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.5281/zenodo.23851353","doi":"https://doi.org/10.5281/zenodo.23851353","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23851353","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"doi:10.5281/zenodo.23851354","doi":"https://doi.org/10.5281/zenodo.23851354","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23851354","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.5281/zenodo.23851353","doi":"https://doi.org/10.5281/zenodo.23851353","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23851353","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7160955177","https://openalex.org/W3012856553","https://openalex.org/W2159132210","https://openalex.org/W4392391975","https://openalex.org/W2332600596","https://openalex.org/W7162132141","https://openalex.org/W2579646645","https://openalex.org/W4406934347","https://openalex.org/W11858539","https://openalex.org/W4410031981"],"abstract_inverted_index":{"Neuroleptic":[0],"agents,":[1,114],"encompassing":[2],"both":[3],"first-generation":[4],"and":[5,41,83,100,138,148,157,170,184,205],"second-generation":[6],"antipsychotics,":[7],"represent":[8],"a":[9,46],"pharmacologically":[10],"heterogeneous":[11],"class":[12],"of":[13,49,60,89,117,131,191],"medications":[14],"with":[15,37,66,115,142,160],"expanding":[16,189],"clinical":[17,67,200],"applications":[18],"beyond":[19],"traditional":[20],"psychiatric":[21],"indications.":[22],"While":[23],"their":[24],"therapeutic":[25],"efficacy":[26],"primarily":[27],"derives":[28],"from":[29,70],"dopamine":[30],"D2":[31],"receptor":[32,43],"antagonism,":[33],"the":[34,57,106,135,164],"intricate":[35],"interplay":[36],"serotonergic,":[38],"histaminergic,":[39],"adrenergic,":[40],"cholinergic":[42],"systems":[44],"generates":[45],"complex":[47],"spectrum":[48],"potential":[50],"adverse":[51,125],"effects.":[52],"This":[53],"comprehensive":[54],"review":[55],"examines":[56],"multifaceted":[58],"nature":[59],"neuroleptic":[61,80,90,192],"toxicity,":[62],"integrating":[63],"pharmacodynamic":[64],"principles":[65],"manifestations":[68],"ranging":[69],"mild,":[71],"self-limited":[72],"symptoms":[73],"to":[74,123,163,209],"severe,":[75],"life-threatening":[76],"conditions":[77],"such":[78],"as":[79],"malignant":[81,84],"syndrome":[82],"cardiac":[85,145],"arrhythmias.":[86],"The":[87,127,188],"etiology":[88],"toxicity":[91,214],"reflects":[92],"drug-specific":[93],"receptor-binding":[94],"affinities,":[95],"dose-related":[96],"effects,":[97],"exposure":[98,169],"duration,":[99],"patient-specific":[101],"vulnerabilities.":[102],"Epidemiological":[103],"data":[104],"underscore":[105],"substantial":[107],"public":[108],"health":[109],"burden":[110],"imposed":[111],"by":[112],"these":[113],"thousands":[116],"emergency":[118],"department":[119],"visits":[120],"annually":[121],"attributable":[122],"antipsychotic-related":[124],"events.":[126],"pathophysiology":[128],"involves":[129],"disruption":[130],"dopaminergic":[132],"pathways":[133],"in":[134],"nigrostriatal,":[136],"tuberoinfundibular,":[137],"hypothalamic":[139],"regions,":[140],"coupled":[141],"effects":[143],"on":[144],"potassium":[146],"channels":[147],"multiple":[149],"neurotransmitter":[150],"systems.":[151],"Clinical":[152],"recognition":[153],"demands":[154],"careful":[155],"history-taking":[156],"physical":[158],"examination,":[159],"particular":[161],"attention":[162],"temporal":[165],"relationship":[166],"between":[167],"drug":[168],"symptom":[171],"onset.":[172],"Management":[173],"strategies":[174],"emphasize":[175],"individualized,":[176],"patient-centered":[177],"approaches":[178],"incorporating":[179],"dose":[180],"reduction,":[181],"medication":[182],"switching,":[183],"targeted":[185],"pharmacologic":[186],"interventions.":[187],"use":[190],"agents":[193],"across":[194],"diverse":[195],"patient":[196],"populations":[197],"necessitates":[198],"heightened":[199],"vigilance,":[201],"robust":[202],"monitoring":[203],"protocols,":[204],"coordinated":[206],"interprofessional":[207],"collaboration":[208],"optimize":[210],"outcomes":[211],"while":[212],"minimizing":[213],"risk.":[215]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-11-02T00:00:00"}